Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets, CFDs, OTC options or any of our other products work and whether you can afford to take the high risk of losing your money.

69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

5 Top Stories

Intuitive Falls; ARK Trims TSM; Samsung Wearables

Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.

Intuitive Plummets on Lander Mishap

The Intuitive Machines [LUNR] share price dropped by some 30% Monday, after the space exploration firm announced that its Odysseus moon lander had fallen over and was lying on its side. Despite this, five out of six of the lander’s NASA payloads were still functional and are expected to carry out their objectives. The company went public a year ago, but only 18% of its stock is available to trade.

A New Era for Wearables?

South Korea’s Samsung [005930:KS] is to launch its latest wearable, the Galaxy Ring, which will include sensors which track heart rate and sleep, Hon Pak, the Head of the digital health team at Samsung, told CNBC. The Ring is on display at the Mobile World Congress in Barcelona, which opened yesterday. Elsewhere, Apple is weighing developing new wearable devices, including a fitness ring and smart glasses, Bloomberg reported.

India Weighs Chip Proposals, as ARK Trims TSM

As part of its push to kickstart the domestic chip industry, India is considering funding proposals, including one from Israel’s Tower Semiconductor [TSEM] for a $9bn plant, and another from the Tata Group for a $8bn plant. Meanwhile, Taiwan Semiconductor Manufacturing Company [TSM] opened its first plant in Japan on Saturday. Cathie Wood’s ARK Invest sold shares in the firm for the first time in over two years on Friday.

Zealand Pharma Pops on Obesity Drug Trial

Denmark’s Zealand Pharma [ZEAL:CO] jumped 32% in early trading Monday, following positive results from a trial of its liver disease treatment. The Phase 2 trial of the survodutide drug helped 83% of adults with a form of liver inflammation. The drug has also “demonstrated efficacy” as an obesity treatment, and is currently undergoing five Phase 3 trials, reported CNBC. The US Food and Drug Administration has given it a fast-track designation.

Li Auto’s Powerful Q4

Li Auto [LI] reported total revenues of RMB41.7bn in Q4 2023, an increase of 136.4% on the year-ago quarter. Total deliveries for the quarter were at 131,805 vehicles, a 184.6% increase. BYD [1211:HK], for its part, is showing off several new models at the Geneva car show this week, among them a sport utility vehicle that can float on water. The electric vehicle giant is aggressively courting the European market.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

Latest articles